Abstract
Severe acute respiratory disease coronavirus 2 (SARS-COV-2) first emerged in Wuhan, China, in December 2019 and has caused a global pandemic of a scale unprecedented in the modern era. People infected with SARS-CoV-2 can be asymptomatic, moderate symptomatic or develop severe COVID-19. Other than the typical acute respiratory distress syndrome (ARDS), patients with moderate or severe COVID-19 also develop a distinctive systemic coagulopathy, known as COVID-19-associated coagulopathy (CAC), which is different from sepsis-related forms of disseminated intravascular coagulation (DIC). Endotheliopathy or endotheliitis are other unique features of CAC. The endothelial cell perturbation can further increase the risk of thrombotic events in COVID-19 patients. In this review, we will summarize the current knowledge on COVID-19 coagulopathy and the possible mechanisms for the condition. We also discuss the results of clinical trials testing methods for mitigating thrombosis events in COVID-19 patients.
【저자키워드】 COVID-19, Endotheliitis, Coagulopathy, NETs, CAC, 【초록키워드】 ARDS, coronavirus, clinical trial, thrombosis, severe COVID-19, knowledge, risk, global pandemic, Asymptomatic, symptomatic, Other, moderate, mechanism, COVID-19 patients, acute respiratory distress, Disseminated intravascular coagulation, Endothelial cell, acute respiratory disease, syndrome, feature, event, thrombotic event, Wuhan, China, develop, caused, form, unique, infected with SARS-CoV-2, patients with moderate, 【제목키워드】 clinical trial, anticoagulation,